Callan Family Office LLC Buys Shares of 1,805 IQVIA Holdings Inc. (NYSE:IQV)

Callan Family Office LLC bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,805 shares of the medical research company’s stock, valued at approximately $355,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Smith Group Asset Management LLC acquired a new stake in IQVIA during the 4th quarter valued at approximately $1,616,000. Simplify Asset Management Inc. boosted its holdings in shares of IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after buying an additional 3,894 shares in the last quarter. Nordea Investment Management AB boosted its holdings in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares in the last quarter. Hickory Asset Management Inc. bought a new position in shares of IQVIA during the 4th quarter worth approximately $941,000. Finally, Fifth Third Bancorp boosted its holdings in shares of IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after buying an additional 1,521 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IQV. Stephens began coverage on IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price on the stock. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Tuesday, March 4th. Morgan Stanley increased their target price on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Stifel Nicolaus cut their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, Citigroup cut their target price on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Trading Down 1.5 %

Shares of IQVIA stock opened at $188.72 on Tuesday. IQVIA Holdings Inc. has a 1 year low of $179.28 and a 1 year high of $261.72. The firm has a market cap of $33.27 billion, a PE ratio of 25.16, a P/E/G ratio of 1.99 and a beta of 1.50. The stock has a fifty day moving average price of $197.62 and a 200-day moving average price of $212.24. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.